What is Nucleus Genomics?
Founded in 2021 and headquartered in New York, NY, Nucleus Genomics operates as a sophisticated consumer genetic testing and analysis platform. The company bridges the gap between complex genomic data and actionable health insights, providing users with a streamlined interface to interpret their biological markers. By leveraging advanced bioinformatics, Nucleus Genomics aims to democratize access to personalized health information, positioning itself as a critical player in the burgeoning field of preventative medicine and data-driven diagnostics.
How much funding has Nucleus Genomics raised?
Nucleus Genomics has raised a total of $31.5M across 3 funding rounds:
Angel/Seed
$3.5M
Unspecified
$14M
Series A
$14M
Angel/Seed (2021): $3.5M, investors not publicly disclosed
Unspecified (2022): $14M led by Seven Seven Six
Series A (2025): $14M supported by Seven Seven Six and Founders Fund
Key Investors in Nucleus Genomics
Seven Seven Six
Seven Seven Six is an early-stage venture capital firm that focuses on innovation at the crossroads of product and people. The firm aims to empower startups by providing not just capital but also operational support and insights.
Founders Fund
Founders Fund invests in the world's most important and valuable companies across all geographies, sectors and stages, pursuing a founder-friendly investment strategy.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Nucleus Genomics?
With the successful closure of this Series A financing, Nucleus Genomics is expected to prioritize the enhancement of its analytical engine and the expansion of its consumer-facing service offerings. The strategic focus will likely shift toward scaling operational capacity and deepening its research capabilities to maintain a competitive edge in the genomics market. As the company transitions from its early-stage development phase into a more mature growth cycle, the integration of advanced machine learning models will be essential to refining the accuracy and utility of its genetic reports. Investors are closely monitoring how the firm will utilize this capital to navigate regulatory landscapes and capture a larger share of the personalized wellness market.
See full Nucleus Genomics company page
